

になったことは、基礎研究が実用化に結びついた好例と言える。TTPの治療には、ADAMTS13補充を目的として新鮮凍結血漿が使用されているが、現在、組換えADAMTS13製剤の開発が進んでおり、治療法の改善も期待できる。反面、ADAMTS13活性の低下が顕著でないTTP症例や、ADAMTS13活性低下が目立つHUSなど、発症機序を明確に説明できない病態も存在する。非典型溶血性尿毒症症候群(atypical HUS : aHUS)や深部静脈血栓症(deep vein thrombosis : DVT)とADAMTS13の関連も詳しく調べる価値があろう。ADAMTS13によるVWF切断機構にもまだ不明の部分があり、興味深い知見も得られつつある。これからの研究の進展が楽しみである。

本稿で紹介した成果は、国立循環器病研究センター分子病態部の宮田敏行部長をはじめとした研究室構成員、病院の小久保喜弘医長や宮田茂樹医長、奈良県立医科大学の藤村吉博教授、松本雅則准教授、化血研の副島見事博士など、多くの方々との共同研究で得られたものであり、ここに感謝の意を表します。

## § 文 献

- 1) Moschcowitz E : Hyaline thrombosis of the terminal arterioles and capillaries ; a hitherto undescribed disease. Proc NY Pathol Soc 1924;24:21-4.
- 2) Moake JL, Rudy CK, Troll JH et al : Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307(23):1432-5.
- 3) Asada Y, Sumiyoshi A, Hayashi T, et al : Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985;38(5): 469-79.
- 4) Furlan M, Robles R, Lämmle B : Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87(10): 4223-34.

- 5) Tsai HM : Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87(10):4235-44.
- 6) Soejima K, Mimura N, Hirashima M, et al : A novel human metalloprotease synthesized in the liver and secreted into the blood : possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001;130 (4):475-80.
- 7) Zheng X, Chung D, Takayama TK, et al : Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276(44):41059-63.
- 8) Levy GG, Nichols WC, Lian EC, et al : Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413 (6855):488-94.
- 9) Akiyama M, Takeda S, Kokame K, et al : Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA 2009;106(46):19274-9.
- 10) Gao W, Zhu J, Westfield LA, et al : Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases. J Biol Chem 2012;287(32):26944-52.
- 11) Kokame K, Matsumoto M, Fujimura Y, et al : VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004;103(2):607-12.
- 12) Kokame K, Nobe Y, Kokubo Y, et al : FRET-S-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129(1):93-100.
- 13) Kato S, Matsumoto M, Matsuyama T, et al : Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006;46(8):1444-52.
- 14) Kokame K, Matsumoto M, Soejima K, et al : Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002;99(18):11902-7.
- 15) Fujimura Y, Matsumoto M, Isonishi A, et al : Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J

- Thromb Haemost 2011;9(Suppl 1):283-301.
- 16) Kokame K, Aoyama Y, Matsumoto M, et al : Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome. *J Thromb Haemost* 2008;6(1):213-5.
  - 17) Kokame K, Kokubo Y, Miyata T : Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw-Schulman syndrome. *J Thromb Haemost* 2011;9(8):1654-6.
  - 18) Akiyama M, Kokame K, Miyata T : ADAMTS13 P475S polymorphism causes a lowered enzymatic activity and urea lability in vitro. *J Thromb Haemost* 2008;6(10):1830-2.
  - 19) Akiyama M, Nakayama D, Takeda S, et al : Crystal structure and enzymatic activity of an ADAMTS-13 mutant with the East Asian-specific P475S polymorphism. *J Thromb Haemost* 2013;11(7):1399-406.
  - 20) Kokame K, Sakata T, Kokubo Y, et al : von Willebrand factor-to-ADAMTS13 ratio increases with age in a Japanese population. *J Thromb Haemost* 2011;9(7):1426-8.
  - 21) Banno F, Kaminaka K, Soejima K, et al : Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease. *J Biol Chem* 2004;279(29):30896-903.
  - 22) Banno F, Kokame K, Okuda T, et al : Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. *Blood* 2006;107(8):3161-6.
  - 23) Motto DG, Chauhan AK, Zhu G, et al : Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. *J Clin Invest* 2005;115(10):2752-61.
  - 24) Fujioka M, Hayakawa K, Mishima K, et al : ADAMTS13 gene deletion aggravates ischemic brain damage : a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. *Blood* 2010;115(8):1650-3.
  - 25) Doi M, Matsui H, Takeda H, et al : ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. *Thromb Haemost* 2012;108(6):1236-8.
  - 26) Banno F, Chauhan AK, Kokame K, et al : The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. *Blood* 2009;113(21):5323-9.

